In a significant development in the fight against melanoma, the University of Cincinnati Cancer Center has revealed promising results from their latest Phase 2 clinical trial. The study, focusing on a combination of therapy using oncolytic viruses and immunotherapy drugs, has shown an increased effectiveness in treating patients who previously did not respond to standard treatments. Dr. Trisha Wise-Draper, leading the research team, announced the findings at the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting.
The IGNYTE trial tested RP1, a genetically modified herpes simplex type 1 virus, alongside nivolumab, a drug that targets PD-1 protein receptors on tumors. These receptors are often used by cancer cells to evade the immune system. By combining these two therapies, the team aimed to not only destroy tumors directly but also to amplify the body's own immune response against melanoma. According to the University of Cincinnati Cancer Center, about one-third of the 140 patients in the trial experienced a favorable response to the treatment.
"The trial itself was positive in that approximately one-third of the patients with refractory melanoma will respond to this combination, and responses are durable,” according to UC News, Wise-Draper was quoted by her own institution. Not only has the combination proven effective, but it has also been well-tolerated by patients, an important consideration in cancer therapies, where side effects often compromise quality of life.
Wise-Draper, a professor of medicine in the Division of Hematology/Oncology, and a pivotal figure in the advancement of cancer treatment strategies at UC's College of Medicine, also holds the position of deputy director of UC's Office of Clinical Research. Her team's work suggests that using RP1 can aid the immune system to infiltrate and activate within tumors, a crucial step for patients whose cancers have become resistant to PD1 inhibitors. This breakthrough represents a beacon of hope for those grappling with melanoma's resilient shadows, offering a potential path to long-term disease control.
